SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-023113
Filing Date
2021-09-20
Accepted
2021-09-20 09:15:34
Documents
13
Period of Report
2021-09-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41886
2 ex99-1.htm EX-99.1 38050
  Complete submission text file 0001493152-21-023113.txt   253096

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE rspi-20210914.xsd EX-101.SCH 3027
4 XBRL LABEL FILE rspi-20210914_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE rspi-20210914_pre.xml EX-101.PRE 22360
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3292
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 211262241
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences